Notice: This company has been marked as potentially delisted and may not be actively trading. NGM Biopharmaceuticals (NGM) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsightOctober 8, 2024 | finance.yahoo.comRenal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightSeptember 24, 2024 | finance.yahoo.comCEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel Growth by 2034 | DelveInsightSeptember 17, 2024 | finance.yahoo.comPharmaceutical Intermediates Market Size To Reach USD 14.0 Billion By 2033, at 13.4% CAGR: Insights by Dimension Market ResearchSeptember 9, 2024 | finance.yahoo.comPsychedelic Stock Deep Dive: Atai Life SciencesSeptember 3, 2024 | seekingalpha.comTHE NATIONAL BLACK COLLEGE ALUMNI HALL OF FAME FOUNDATION, INC. ANNOUNCES THE HONOREES FOR INDUCTION INTO THE 2024 HALL OF FAMEAugust 30, 2024 | finance.yahoo.com3 Swedish Growth Companies With Up To 30% Insider OwnershipAugust 14, 2024 | finance.yahoo.comSwedish Growth Companies With High Insider Ownership In July 2024July 26, 2024 | finance.yahoo.comSino Biopharmaceutical Ltd 01177July 26, 2024 | morningstar.comSwedish Growth Companies With High Insider Ownership And 31% ROEJuly 25, 2024 | finance.yahoo.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock Quotes, Forecast and News SummaryJuly 22, 2024 | benzinga.comMerck to buy eye drug developer for $1.3BMay 29, 2024 | finance.yahoo.comGlobal Ambulatory Surgical Centers Market is Projected to Boost at a Moderate Growth Rate of ~6% by 2030 | DelveInsightMay 23, 2024 | finance.yahoo.comGlobal Infection Prevention and Control Market is Likely to Increase at a Steady Growth Rate of ~6% by 2030 | DelveInsightMay 22, 2024 | finance.yahoo.comSwedish Exchange Highlights Three Growth Companies With High Insider OwnershipMay 13, 2024 | finance.yahoo.comNGM Biopharmaceuticals, Inc.: NGM Bio Announces Closing of Tender OfferApril 5, 2024 | finanznachrichten.deNGM Bio Announces Closing of Tender OfferApril 5, 2024 | globenewswire.comTrading was temporarily halted for "NGM" at 07:04 PM with a stated reason of "News pending."April 5, 2024 | marketbeat.comNGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingMarch 19, 2024 | globenewswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMMarch 13, 2024 | businesswire.comHow a VC and a biotech founder plan to create a new biotech modelMarch 12, 2024 | bizjournals.comOracle, Dollar General upgraded: Wall Street's top analyst callsMarch 12, 2024 | msn.comNGM Biopharmaceuticals (NASDAQ:NGM) Lowered to "Market Perform" at Raymond JamesRaymond James cut NGM Biopharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Tuesday.March 12, 2024 | marketbeat.comNGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | globenewswire.comNGM Biopharmaceuticals (NASDAQ:NGM) Downgraded to Neutral at B. RileyB. Riley lowered NGM Biopharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Wednesday.February 29, 2024 | marketbeat.comTD Cowen Downgrades NGM Biopharmaceuticals (NGM)February 29, 2024 | msn.comTD Cowen Downgrades NGM Biopharmaceuticals (NASDAQ:NGM) to Market PerformTD Cowen lowered NGM Biopharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Wednesday.February 28, 2024 | marketbeat.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMFebruary 27, 2024 | businesswire.comNGM Biopharmaceuticals (NASDAQ:NGM) Downgraded by CitigroupCitigroup cut NGM Biopharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Tuesday.February 27, 2024 | marketbeat.comThe Column Group moves forward with plan to take NGM Bio privateFebruary 26, 2024 | bizjournals.comNGM Biopharmaceuticals, Inc.: NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 26, 2024 | finanznachrichten.deNGM Bio To Be Acquired By Affiliates Of The Column Group, LPFebruary 26, 2024 | markets.businessinsider.comNGM to go private through deal with investment firmFebruary 26, 2024 | finance.yahoo.comNGM Biopharmaceuticals Shares Drop 20% After $1.55/Shr Buyout OfferFebruary 26, 2024 | marketwatch.comNGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to ShareholdersFebruary 26, 2024 | businesswire.comNGM Biopharmaceuticals Gets Buyout Offer From Column Group AffliatesFebruary 26, 2024 | marketwatch.comNGM Bio to go private in a $135M deal with Atlas NeonFebruary 26, 2024 | msn.comNGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 26, 2024 | globenewswire.comTrading was temporarily halted for "NGM" at 08:02 AM with a stated reason of "News pending."February 26, 2024 | marketbeat.comNGM Biopharmaceuticals (NGM) Scheduled to Post Earnings on MondayNGM Biopharmaceuticals (NASDAQ:NGM) will be releasing earnings on Monday, February 26, Yahoo Finance reports.February 25, 2024 | marketbeat.comAscites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsightFebruary 22, 2024 | finance.yahoo.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 20, 2024 | finance.yahoo.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 20, 2024 | globenewswire.comNGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Sees Significant Increase in Short InterestNGM Biopharmaceuticals, Inc. (NASDAQ:NGM - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 1,680,000 shares, an increase of 9.1% from the January 15th total of 1,540,000 shares. Based on an average daily volume of 961,800 shares, the short-interest ratio is currently 1.7 days. Currently, 4.1% of the company's stock are sold short.February 17, 2024 | marketbeat.comNGM Biopharmaceuticals, Inc. (NGM)February 13, 2024 | ca.finance.yahoo.comLooking Into NGM Biopharmaceuticals's Recent Short InterestJanuary 19, 2024 | benzinga.comNGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceJanuary 17, 2024 | finance.yahoo.comNGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Short Interest Down 34.4% in DecemberNGM Biopharmaceuticals, Inc. (NASDAQ:NGM - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,640,000 shares, a decrease of 34.4% from the December 15th total of 2,500,000 shares. Based on an average daily trading volume, of 993,600 shares, the short-interest ratio is currently 1.7 days. Currently, 4.0% of the shares of the company are short sold.January 14, 2024 | marketbeat.comNGM Biopharma gains on Phase 1 data update for cancer therapyJanuary 9, 2024 | msn.comNGM Biopharmaceuticals Stock (NASDAQ:NGM) Dividends: History, Yield and DatesJanuary 9, 2024 | benzinga.com Get NGM Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. NGM Media Mentions By Week NGM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGM News Sentiment▼0.000.49▲Average Medical News Sentiment NGM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGM Articles This Week▼01▲NGM Articles Average Week Get NGM Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ENTA News Today LIAN News Today PHXM News Today DRTSW News Today BCTXW News Today EFTRW News Today FBIOP News Today GOVXW News Today BMY News Today AMGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NGM Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NGM Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
